Drugs / Lysogenic HSV virus
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06741982 | Dec 2024 → Dec 2026 expected | head and neck squamous cell carcinoma | West China Hospital | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07010120 | Jun 2025 → May 2027 expected | head and neck squamous cell carcinoma | West China Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lysogenic HSV virus | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06741982 ↗ |
| Modality | Other / unclassified | “Oncolytic herpes simplex virus (HSV) has the ability to specifically replicate within tumor cells and lyse them.” NCT06741982 ↗ |